AAP
UTHR icon

Ardsley Advisory Partners’s United Therapeutics UTHR Stock Holding History

Ardsley Advisory Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3M Sell
30,000
-20,000
-40% -$11.3M 1.69% 13
2026
Q1 		$29.6M Buy
+50,000
New +$24.9M 3.78% 2
2023
Q3 		– Sell
-40,000
Closed -$8.83M – 157
2023
Q2 		$8.83M Buy
+40,000
New +$8.86M 1.49% 19

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Ardsley Advisory Partners's UTHR Position: Q2 2026 in Review

Ardsley Advisory Partners reduced its United Therapeutics (UTHR) stake by 40% in Q2 2026, selling an estimated $11.3M and leaving 30,000 shares worth $16.3M. The position accounts for 1.69% of the portfolio, ranked #13.

Ardsley Advisory Partners first reported a position in UTHR in Q2 2023 and has held it in 3 quarters since. The position peaked at $29.6M in Q1 2026. 881 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Ardsley Advisory Partners held 30,000 shares of United Therapeutics worth $16.3M as of Q2 2026.
  • Ardsley Advisory Partners sold 20,000 United Therapeutics shares in Q2 2026, an estimated $11.3M.
  • United Therapeutics made up 1.69% of Ardsley Advisory Partners's portfolio in Q2 2026, its #13 holding.
  • Ardsley Advisory Partners first reported a position in United Therapeutics in Q2 2023 and has held it in 3 quarters since.
  • Ardsley Advisory Partners's United Therapeutics position peaked at $29.6M in Q1 2026.
  • 881 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Ardsley Advisory Partners's 13F filing for Q2 2026, filed 13 Jul 2026.